Christy Young, MD
Neurology · Loveland, CONPI 1730304593
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,269 of the $43,206 with a category attached, or 93.2%. AbbVie accounts for 72.6% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $16,958, more than ten times the $730 reported in 2019.
Across 49 payments — averaging $881.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- Pfizer$10K
- Livanova USA, Inc.$582
- Lundbeck LLC$222
- Teva Pharmaceuticals USA, Inc.$149
- Neurocrine Biosciences, Inc.$140
- plus $299 from 4 others
What the payments were for
- Consulting fees$9152%
- Speaking & faculty fees$40,26993%
- Travel & lodging$2070%
- Food & beverage$1,7134%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $31,351 |
| Pfizer | 5 | $10,464 |
| Livanova USA, Inc. | 2 | $582 |
| Lundbeck LLC | 3 | $222 |
| Teva Pharmaceuticals USA, Inc. | 2 | $149 |
| Neurocrine Biosciences, Inc. | 1 | $140 |
| Biohaven Pharmaceuticals, Inc. | 1 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $92 |
| SK Life Science, Inc. | 1 | $52 |
| Novartis | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$23,444
- UBRELVY$16,513
- ZAVZPRET$9,450
- NURTEC ODT$1,039
- VNS Therapy$582
- ONGENTYS$140
- INGREZZA$140
- VYEPTI$125
How this compares
$43,206 in reported general payments places this provider in the 85th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 103 | $153,665 |
| VumerityDiroximel Fumarate | 11 | $111,380 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $96,122 |
| Emgality PenGalcanezumab-Gnlm | 87 | $94,823 |
| Nurtec OdtRimegepant Sulfate | 72 | $84,786 |
| UbrelvyUbrogepant | 69 | $71,913 |
| NuplazidPimavanserin Tartrate | 11 | $53,913 |
| RytaryCarbidopa/Levodopa | 42 | $53,845 |
| EpidiolexCannabidiol (Cbd) | 13 | $39,395 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $38,721 |
| ReyvowLasmiditan Succinate | 33 | $33,654 |
| XcopriCenobamate | 11 | $15,109 |
| Dihydroergotamine Mesylate | 16 | $12,716 |
| Zolmitriptan | 20 | $10,772 |
| Sumatriptan Succinate | 133 | $8,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $31,351 | $225,578172 claims |
| PfizerNurtec Odt | $10,464 | $84,78672 claims |
| SK Life Science, Inc.Xcopri | $52 | $15,10911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 334 neurology providers in Colorado.
Other neurology in Loveland
- Bridget OlleschLoveland$38K
- Tamara MillerFort Collins$1.4M
- Justin MoonDenver$1.4M
- Ravi ShahParker$1.3M
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Jeffrey BennettAurora$605K
- Beverly GilderLone Tree$558K
- Michael AmentDenver$457K
- Enrique AlvarezAurora$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.